• Ceramides Drive RGNNV Infection Through Autophagy

  2026-08-18

  Zhang and colleagues used global lipidomics and functional perturbation assays to show that red-spotted grouper nervous necrosis virus reshapes host sphingolipid metabolism, with ceramide accumulation supporting viral replication. The study links capsid-protein-associated ceramide remodeling to autophagy and identifies ceramide synthesis as a potential intervention point in fish nodavirus disease.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-08-18

  The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 and LLY507 in animal and tubular epithelial cell models, the authors connect SMYD2 inhibition with reduced epithelial-mesenchymal transition, extracellular matrix accumulation, inflammatory signaling, and Smad3/STAT3 activation.

• NLRP10, Keratinocyte Survival, and AD Barrier Function

  2026-08-17

  The reference study identifies NLRP10 as a regulator of epidermal homeostasis that supports keratinocyte survival, p63-dependent differentiation, and barrier integrity in atopic dermatitis. Its combination of patient-sample analysis, air-lift human skin equivalents, and mechanistic investigation of caspase-8 and p63 provides a useful framework for connecting genetic susceptibility with tissue-level barrier dysfunction.

• MG-262 for Proteasome and Muscle Proteostasis

  2026-08-17

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) enables reversible, cell-permeable disruption of proteasome chymotryptic activity for mechanistic studies of ubiquitin accumulation, apoptosis, and cell-cycle control. Paired with the CMA reporter strategy used in recent skeletal-muscle research, it helps distinguish proteasomal stress from lysosomal proteostasis responses.

• 0.4% Trypan Blue Solution: Practical Guide

  2026-08-16

  0.4% Trypan Blue Solution supports rapid cell viability measurement, cell counting, and live/dead cell discrimination by staining cells with compromised membranes. It is intended for controlled research workflows, including selected cytotoxicity assays, but not for diagnostic, clinical, or medical use.

• Fluorouracil Workflows for Solid Tumor Research

  2026-08-15

  Build more reproducible Fluorouracil assays by combining concentration–time profiling with orthogonal measurements of DNA synthesis, viability, and apoptosis. This workflow also shows how findings from Wnt/β-catenin research can inform hypothesis-driven colon and breast cancer research without overstating combination effects.

• MMP7, EMT, and Liver Fibrosis in Biliary Atresia

  2026-08-14

  A 2026 study identifies MMP7 as a mechanistic driver of biliary atresia-associated liver fibrosis by cleaving E-cadherin and promoting β-catenin nuclear translocation during epithelial–mesenchymal transition. By integrating patient samples, transcriptomic analysis, biliary epithelial cell experiments, and a chronic mouse model, the work connects a clinical biomarker with a potentially actionable fibrotic pathway.

• From Barrier Biology to Faster Genotyping

  2026-08-14

  Mechanistic studies of Lactobacillus gasseri, NR1I3, and E-cadherin show why genotype-aware model selection matters in translational research. This article connects that biology with a rapid, single-tube PCR workflow for insects, tissues, fishes, and cells while clarifying performance boundaries and validation priorities.

• Fluorouracil: From TS Inhibition to Translation

  2026-08-13

  Fluorouracil, also known as 5-Fluorouracil, remains a powerful translational anchor because its thymidylate synthase mechanism connects molecular pharmacology with measurable replication stress and tumor-cell death. This article links established Fluorouracil (Adrucil) benchmarks to emerging SMC2 and SMC4 findings in breast cancer research, outlines experimental design principles for colon cancer research, and explains why target engagement, exposure control, and biomarker context should guide the next generation of solid-tumor studies.

• PTEN mRNA: From Pathway Repair to Delivery

  2026-08-13

  A translational framework for using EZ Cap™ Human PTEN mRNA to connect PTEN biology, Cap 1 and poly(A) design, nanoparticle delivery, and preclinical cancer research.

• AZD0156: Practical ATM Kinase Inhibitor Workflows

  2026-08-12

  AZD0156 is a highly selective ATM kinase inhibitor for connecting DNA damage signaling with repair, checkpoint, and metabolic phenotypes. This workflow-focused guide covers formulation, target-engagement assays, combination studies, and troubleshooting for cancer therapy research.

• Fluorescence to Translation in Antibody Research

  2026-08-12

  How a Cy3 secondary antibody can strengthen antibody characterization, assay comparability, and translational decision-making in orthopoxvirus research.

• CTOP for μ-Opioid Receptor Research

  2026-08-11

  CTOP provides a selective pharmacological switch for separating μ-opioid receptor effects from downstream circuit activity in binding, signaling, and pain-model experiments. This guide translates recent brain-to-spinal findings into practical assay designs, controls, and troubleshooting strategies for opioid receptor research.

• Neurotensin: Designing Cleaner GPCR Assays

  2026-08-11

  Neurotensin is a powerful perturbation tool for studying NTR1 signaling, receptor recycling, and miR-133α modulation in gastrointestinal cells. This article presents a measurement-aware workflow that connects GPCR biology with fluorescence-interference control without confusing assay methodology with direct mechanistic evidence.

• Capecitabine for Tumor-Stroma Drug Screening

  2026-08-10

  Capecitabine provides a practical way to investigate prodrug activation, tumor–stroma interactions, and treatment resistance in patient-derived models. This workflow shows how to deploy it in gastric assembloids and colon cancer research while separating validated findings from assay-specific optimization.

8109 records 4/541 page Previous Next 12345 下5页 Last page